BAYN Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €28.42 |
52 Week High | €61.91 |
52 Week Low | €24.96 |
Beta | 0.97 |
1 Month Change | -0.58% |
3 Month Change | -15.14% |
1 Year Change | -50.38% |
3 Year Change | -47.33% |
5 Year Change | -52.95% |
Change since IPO | 108.67% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way
Jan 18Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?
Dec 27Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt
Oct 15Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 05Is Bayer (ETR:BAYN) A Risky Investment?
Jun 28Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky
Dec 07Is Bayer (ETR:BAYN) A Risky Investment?
Aug 18Shareholder Returns
BAYN | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 8.4% | 4.0% | 2.5% |
1Y | -50.4% | -24.6% | 7.0% |
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned -24.6% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 7% over the past year.
Price Volatility
BAYN volatility | |
---|---|
BAYN Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BAYN's share price has been volatile over the past 3 months.
Volatility Over Time: BAYN's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,931 | Bill Anderson | https://www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYN fundamental statistics | |
---|---|
Market cap | €27.92b |
Earnings (TTM) | -€2.94b |
Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.5x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYN income statement (TTM) | |
---|---|
Revenue | €47.64b |
Cost of Revenue | €19.75b |
Gross Profit | €27.89b |
Other Expenses | €30.83b |
Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -2.99 |
Gross Margin | 58.55% |
Net Profit Margin | -6.17% |
Debt/Equity Ratio | 132.3% |
How did BAYN perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-4%
Payout RatioDoes BAYN pay a reliable dividends?
See BAYN dividend history and benchmarksBayer dividend dates | |
---|---|
Ex Dividend Date | Apr 29 2024 |
Dividend Pay Date | May 02 2024 |
Days until Ex dividend | 31 days |
Days until Dividend pay date | 34 days |
Does BAYN pay a reliable dividends?
See BAYN dividend history and benchmarks